Box-Behnken Design Approach for Optimization of a Liquid Chromatographic Method for the Determination of Anti Leukemic Drugs in Bulk and Pharmaceutical Formulations
R. Suresh, M. Swamivelmanickam, S. Sivakrishnan
Journal of Pharmaceutical Research International · pp. 67–77 · Published 17 Dec 2020
10.9734/jpri/2020/v32i3530980Abstract
To develop and validate a RP-HPLC method for the determination of selected anti- leukemic drugs in bulk and pharmaceutical formulations using Design of experiments. Development of the chromatographic method is based on design of experiments (DOE) approach, utilizing two level full factorial design for screening and Box-Behnken experimental design for optimization. In order to identify the significant parameters for the optimization, by simultaneously registering the main, interaction and quadratic effects of three factors such as volume of methanol (X1), concentration of buffer(X2) and flow rate (X3) on the selected responses like capacity factor K1 of first eluted peak (Y1), resolution of critical peaks RS (1,2) (Y2) and amp; RS (2,3) (Y3) and retention time of last peak tR4 (Y4) as responses. Analytes were separated on a Onyx monolithic- C18 (100×4.6mm) with mobile phase comprising Potassium dihydrogen orthophosphate (0.01M), Methanol and Acetonitrile in ratio of (30:34.29:35.71), with flow rate of 0.723 mL/min and pH 3.5 adjusted with dilute orthophosphoric acid. Total chromatographic analysis time per samples was approximately 5 minutes with DST(IS), IMT, IBT and SFN eluting with retention times of 2.64, 3.05, 3.81 and 4.59 minutes respectively. Calibration curves were linear over selected range 0.997 for the all analytes. The method was sensitive with the LODs were 10.457, 13.07 and 26.169 ng/mL and LOQs were 31.68, 39.6 and 79.3ng/mL for IMT, IBT and SFN respectively. Inter and Intra-day precision data (in terms of %RSD) was fond to be less than ≥3 respectively, Recoveries ranged ≥102±2% for Imatinib- Gleevec, Ibrutinib- Imbruvica and Sorafenib- Nexavar. The obtained results corroborated the potential of the proposed method for determination of all the three anti-leukemic drugs for routine analysis for products of similar type and composition.
Cited by 5
Department of Quality Assurance, R. C. Patel Institute of Pharmaceutical Education and Research, Near Karwand naka, Shirpur 425405, India, SWATI DEVENDRA RAYSING, ASHISH PRAKASH GORLE · Cellulose Chemistry and Technology · 2025
Fahime Dehghan, Alimorad Rashidi, Fahime Parvizian · Scientific Reports · 2023
Soheila Sharafinia, Abdolhadi Farrokhnia, Ensieh Ghasemian Lemraski · Materials Chemistry and Physics · 2022
Soheila Sharafinia, Alimorad Rashidi, Behnam Babaei · 2022
Soheila Sharafinia, Alimorad Rashidi, Behnam Babaei · Scientific Reports · 2023
Related research
- A Case Report of an Advanced Stage Gastrointestinal Stromal Tumor Successfully Treated by Surgery and Imatinib — shares topic coverage
- Early Haematological Response and Short-Term Safety of Frontline Imatinib in Adults with Chronic Myeloid Leukaemia: A Retrospective Study in a Resource-Limited Setting — shares topic coverage
- Hematological, Biochemical and Demographic Profile at Diagnosis of Chronic Myeloid Leukemia in Patients Assigned to a Third-level Medical Unit in Mexico — shares topic coverage
- Successful Treatment of Clonal Eosinophilia with FIP1L1-PDGFRA Rearrangement with Low Dose IMATINIB – A Case Report — shares topic coverage
- Autoimmune Hemolytic Anemia in a Patient with Chronic Myeloid Leukemia: Case Report — shares topic coverage
Article metrics
Real usage data collected on this platform.
0
Page views
0
PDF downloads
0
Outbound clicks
5
Citations
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
No views recorded yet.
Traffic sources
Referring site, by host.
No traffic recorded yet.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.